GE HealthCare Technologies Inc. GEHC recently announced the launch of CleaRecon DL, an innovative AI-based deep learning ...

Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...

If mishandled, this move could undermine public trust in the FDA and squander a once-in-a-generation opportunity to lead the ...

AdvaMed, the MedTech Association, released its AI Policy Roadmap (the Roadmap) outlining policy priorities for Congress and the U.S. Food and Drug Administration (FDA).

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

WASHINGTON, D.C.—FDA Commissioner Martin Makary, M.D., offered more details into the agency’s recently announced plans to ...

AI adoption in pharma can be slow, but failing to scale these new tools across your organization is a missed opportunity.

The unintentional theme of today’s issue is the struggle for control over how we implement AI in the U.S. On one side, where ...

There could be an upside to incorporating AI for the FDA. Using AI to assist in final drug reviews would "represent a chance ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

Looking Ahead The FDA’s full-scale adoption of AI technology represents a leap forward in regulatory oversight. By ...